Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.76%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.32 per share when it actually produced a loss of $0.35, delivering a surprise of -9.38%.Over the last four quarters, the ...

Deramiocel Development and Commercialization - Capricor initiated a rolling BLA submission for deramiocel in October 2024, with full submission expected by year-end 2024, targeting a potential PDUFA date in the second half of 2025[1][4] - Capricor signed a binding term sheet with Nippon Shinyaku for European expansion and commercialization of deramiocel, with potential milestones totaling approximately $1.5 billion[1][5] - Capricor plans to provide clinical data on skeletal muscle myopathy from the Phase 3 HOPE-3 trial to support potential label expansion for deramiocel[4] Financial Performance and Position - Capricor reported Q3 2024 revenues of approximately $2.3 million, down from $6.2 million in Q3 2023, primarily from ratable recognition of $40 million upfront and milestone payments from Nippon Shinyaku[9] - Revenue for Q3 2024 was $2.26 million, a decrease from $6.19 million in Q3 2023[18] - Total revenue for the nine months ended September 30, 2024, was $11.14 million, down from $13.09 million in the same period in 2023[18] - Capricor's Q3 2024 net loss was approximately $12.6 million, or $0.38 per share, compared to a net loss of $6.4 million, or $0.25 per share, in Q3 2023[11] - Net loss for Q3 2024 was $12.56 million, compared to $6.39 million in Q3 2023[18] - Comprehensive loss for Q3 2024 was $12.62 million, compared to $6.46 million in Q3 2023[18] - Capricor's cash position as of September 30, 2024, was approximately $85.0 million, up from $39.5 million at the end of 2023, supported by recent equity offerings[8] - Cash, cash equivalents, and marketable securities increased to $85.03 million as of September 30, 2024, from $39.49 million as of December 31, 2023[18] - Total assets grew to $92.95 million as of September 30, 2024, from $58.73 million as of December 31, 2023[18] - Total liabilities decreased to $24.69 million as of September 30, 2024, from $36.13 million as of December 31, 2023[18] - Total stockholders' equity increased to $68.26 million as of September 30, 2024, from $22.60 million as of December 31, 2023[18] Clinical Trial Results and Data - Capricor presented positive 3-year safety and efficacy results from the HOPE-2 OLE trial, showing improvements in cardiac function and a statistically significant benefit in PUL v2.0 total score[5] StealthX™ Exosome Platform and Project NextGen - Capricor's StealthX™ exosome platform was selected for Project NextGen, with manufacturing underway and delivery to NIAID planned for Q1 2025, with preliminary data expected in Q2 2025[7] Capital Raising and Cash Runway - Capricor completed a public offering of common stock, raising gross proceeds of approximately $86 million, extending its cash runway into 2027[1][8] Manufacturing and Production Expansion - Capricor is exploring GMP production expansion to meet potential product demand in the U.S. and other regions[4]

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Capricor Therapeutics (CAPR) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Capricor Therapeutics is a member of our Medical group, which includes 1024 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gaug ...

Capricor Therapeutics (CAPR) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, th ...

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today the closing of its previously announced underwritten public offering of 5,073,800 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares to cover over allotments, bringing the total gross proceeds to Capricor from the offering to ...

SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the pricing of its underwritten offering of 4,412,000 shares of common stock at a public offering price of $17.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 661,800 shares of its common stock at the public offering price, less the under ...

Core Viewpoint - Capricor Therapeutics has announced a proposed underwritten public offering of its common stock to support the development of its product candidates and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes a 30-day option for underwriters to purchase an additional 15% of the shares sold [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. - The securities are being offered under an effective shelf registration statement filed with the SEC [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the continued development and manufacturing of product candidates, working capital, and general corporate purposes [2]. Group 3: Company Overview - Capricor Therapeutics focuses on cell and exosome-based therapeutics for rare diseases, with its lead product candidate, deramiocel (CAP-1002), in Phase 3 clinical development for Duchenne muscular dystrophy [5]. - The company utilizes its proprietary StealthX™ platform for exosome technology aimed at various therapeutic applications [5]. - Capricor has an exclusive commercialization agreement for deramiocel in the U.S. and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [8].

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Inv ...

-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that it has initiated its rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA), seeking full approval fo ...